PRNewswireNew York [US]/ London [UK]/ Munich [Germany]/ New Delhi [India], February 11: Datar Cancer Genetics (DCG), a global ...

Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Introduction Blood cancer diagnostics refers to the process of detecting and identifying cancers that affect the blood, bone marrow, and lympha ...

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered ...

Wednesday, 2/5/2025 11:15 am-12:15 pm Gerstenzang 124 Molecular Genetics Journal Club (Engineering Faculty Search) Heidi Klumpe, PhD (Postdoctoral Fellow, Boston ...

Within brain health, the robust demand for AD-detect blood tests for assessing Alzheimer's disease risk drives solid growth ...

To bridge geographical barriers, technology-driven solutions like tele-diagnostics are gaining momentum. The integration of ...

Discovery of the molecular defects responsible for these diseases has initiated genetic diagnostics in many countries around the world, including the Middle East, Europe, USA, Japan and Australia.

PLEASE NOTE: The MDU has relocated to Chelsea & Westminster Hospital and is based there from 9 September 2024 onwards. The Molecular Diagnostic Unit (MDU) specialises in providing fast, accurate ...

KBC Group NV raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 132.8% in the fourth quarter, ...

Increase in Healthcare Expenditure and Growth in Non-communicable Diseases Driving Market Growth Egyptian Diagnostic Labs ...